Slump In Generic Submissions Helps US FDA Draw Nearly Even With Approvals

 
• By Derrick Gingery

ANDA approval rates have remained steady, while submission rates dropped compared to prior years.

Generic drugs
The monthly approval rate would be the second-best of the GDUFA era if sustained through the second half of FY 2021. • Source: Alamy

More from Generics

More from Biosimilars & Generics